Envestnet Asset Management Inc. Has $7.38 Million Position in Fresenius Medical Care AG & Co. KGaA $FMS

Envestnet Asset Management Inc. lessened its stake in Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) by 25.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 280,178 shares of the company’s stock after selling 93,783 shares during the period. Envestnet Asset Management Inc.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $7,377,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. TD Waterhouse Canada Inc. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter worth approximately $36,000. Atlantic Union Bankshares Corp bought a new position in Fresenius Medical Care AG & Co. KGaA during the 2nd quarter worth approximately $43,000. Hantz Financial Services Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 568.5% in the 2nd quarter. Hantz Financial Services Inc. now owns 2,079 shares of the company’s stock worth $59,000 after purchasing an additional 1,768 shares during the period. Huntington National Bank boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 219.5% in the 2nd quarter. Huntington National Bank now owns 2,355 shares of the company’s stock valued at $67,000 after purchasing an additional 1,618 shares during the last quarter. Finally, AlphaCore Capital LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the second quarter worth $73,000. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Price Performance

FMS stock opened at $24.40 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.36 and a quick ratio of 1.00. The company’s 50-day moving average is $23.32 and its 200-day moving average is $24.47. The stock has a market capitalization of $14.15 billion, a PE ratio of 17.81, a price-to-earnings-growth ratio of 0.76 and a beta of 0.90. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.94 and a 1 year high of $30.46.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on FMS. Erste Group Bank lowered shares of Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. The Goldman Sachs Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Finally, Zacks Research downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Five equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.